Dermatologic Agents

"Dermatologic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs used to treat or prevent skin disorders or for the routine care of skin.

Descriptor ID	D003879
MeSH Number(s)	D27.505.954.444
Concept/Terms	Dermatologic Agents Dermatologic Agents Dermatological Agents Agents, Dermatological Agents, Dermatologic Dermatologic Agent Agent, Dermatologic Agent, Dermatological Dermatological Agent

Below are MeSH descriptors whose meaning is more general than "Dermatologic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Dermatologic Agents [D27.505.954.444]

Below are MeSH descriptors whose meaning is more specific than "Dermatologic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dermatologic Agents" by people in this website by year, and whether "Dermatologic Agents" was a major or minor topic of these publications.

Bar chart showing 19 publications over 16 distinct years, with a maximum of 2 publications in 2009 and 2011 and 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	1	0	1
2002	1	0	1
2008	0	1	1
2009	2	0	2
2011	1	1	2
2014	2	0	2
2015	0	1	1
2016	1	0	1
2017	1	0	1
2019	1	0	1
2020	0	1	1
2021	0	1	1
2022	1	0	1
2023	1	0	1
2024	0	1	1
2025	1	0	1

Below are the most recent publications written about "Dermatologic Agents" by people in Profiles.

Lebwohl M, Gooderham MJ, Warren RB, Tha?i D, Foley P, Gottlieb AB, Torres T, Popmihajlov Z, Jou YM, Linaberry M, Daamen C, Griffiths CEM. Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis. Clin Exp Dermatol. 2025 Sep 25; 50(10):2030-2036.

View in: PubMed
Delva C, Pearson TF, Harris JE. Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development. Cutis. 2024 Apr; 113(4):156-158.

View in: PubMed
Nicolas SE, Bear MD, Kanaan AO, Coman OA, Dima L. Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis. Am J Ther. 2023 Nov-Dec 01; 30(6):e535-e542.

View in: PubMed
Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nu?ez JJ, Gomez-Escobar L, P?rez-Herrera LC, D?az Martinez JP, Brignardello-Petersen R, Sadeghirad B, Wong MM, Ceccacci R, Zhao IX, Basmaji J, MacDonald M, Chu X, Islam N, Gao Y, Izcovich A, Asiniwasis RN, Boguniewicz M, De Benedetto A, Capozza K, Chen L, Ellison K, Frazier WT, Greenhawt M, Huynh J, LeBovidge J, Lio PA, Martin SA, O'Brien M, Ong PY, Silverberg JI, Spergel JM, Smith Begolka W, Wang J, Wheeler KE, Gardner DD, Schneider L. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023 12; 152(6):1493-1519.

View in: PubMed
Patel D, Svoboda R, Maczuga S, Foulke GT, Helm M. A retrospective claims analysis confirms the cost of most biologic agents for psoriasis is increasing more rapidly than medical inflation. J Am Acad Dermatol. 2023 02; 88(2):490-493.

View in: PubMed
Katz EL, Harris JE. Translational Research in Vitiligo. Front Immunol. 2021; 12:624517.

View in: PubMed
Guo W, Zhu C, Stevens G, Silverstein D. Analyzing the Efficacy of Isotretinoin in Treating Dissecting Cellulitis: A Literature Review and Meta-Analysis. Drugs R D. 2021 Mar; 21(1):29-37.

View in: PubMed
Franciosi E, Blankenship K, Houk L, Rashighi M. Ovoid palatal patch: a clue to anti-TIF1? dermatomyositis. BMJ Case Rep. 2020 Apr 23; 13(4).

View in: PubMed
Van Voorhees AS, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE. Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. J Dermatolog Treat. 2021 May; 32(3):302-309.

View in: PubMed
Bronckers IMGJ, Seyger MMB, West DP, Lara-Corrales I, Tollefson M, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mah? E, Siegfried E, Philipp S, Szalai Z, Vleugels RA, Holland K, Murphy R, Baselga E, Cordoro K, Lambert J, Alexopoulos A, Mrowietz U, Kievit W, Paller AS. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. JAMA Dermatol. 2017 11 01; 153(11):1147-1157.

View in: PubMed

People

Explore

Similar Concepts

Top Journals